Abstract
This study highlights conformationally controlled mechanistic aspects of peptide inhibitors for BACE 1. Peptide inhibitors with reduced molecular weight tend to have cyclic conformation leading to reduced interactions with catalytic motif. Conformation plays a major role in determining potency of peptide inhibitors. An attempt has been made at designing lead compound with reduced molecular weight along with proper conformation suitable for active site and retention of specificity analogous to natural substrate. Reduced molecular weight should hopefully lead to enhanced bioavailability.
Keywords: BACE 1, inhibitors, low molecular weight, interaction energy, docking, aspartic dyad, Alzheimer's, catalytic aspartic
Central Nervous System Agents in Medicinal Chemistry
Title:Conformationally Controlled Mechanistic Aspects of BACE 1 Inhibitors
Volume: 12 Issue: 1
Author(s): M. Sonker, A. Yadav
Affiliation:
Keywords: BACE 1, inhibitors, low molecular weight, interaction energy, docking, aspartic dyad, Alzheimer's, catalytic aspartic
Abstract: This study highlights conformationally controlled mechanistic aspects of peptide inhibitors for BACE 1. Peptide inhibitors with reduced molecular weight tend to have cyclic conformation leading to reduced interactions with catalytic motif. Conformation plays a major role in determining potency of peptide inhibitors. An attempt has been made at designing lead compound with reduced molecular weight along with proper conformation suitable for active site and retention of specificity analogous to natural substrate. Reduced molecular weight should hopefully lead to enhanced bioavailability.
Export Options
About this article
Cite this article as:
M. Sonker, A. Yadav , Conformationally Controlled Mechanistic Aspects of BACE 1 Inhibitors, Central Nervous System Agents in Medicinal Chemistry 2012; 12(1) . https://dx.doi.org/10.2174/187152412800229116
DOI https://dx.doi.org/10.2174/187152412800229116 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety Hippocampal Mean Diffusivity for the Diagnosis of Dementia and Mild Cognitive Impairment in Primary Care
Current Alzheimer Research Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Alzheimer’s Disorder: Epigenetic Connection and Associated Risk Factors
Current Neuropharmacology Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice
Current Alzheimer Research Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy The Role of Malnutrition in Older Persons with Mobility Limitations
Current Pharmaceutical Design Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry TREM2 and the Progression of Alzheimer’s Disease
Current Neurovascular Research